TOKYO, August 2, 2022 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji YasukawaPh.D., “Astellas”) today announced the following changes to its effective management structure October 1, 2022.

1. High direction

  • Appointment of a new CMO
    dr. Tadaaki TaniguchiMD, Ph.D, will be appointed to the new Chief Medical Officer (CMO) effective October 1st2022. He joined Astellas as an executive advisor on July 1, 2022. He is an internationally trained oncology surgeon with extensive industry experience in the development and commercialization of innovative drugs as a senior executive in major global pharmaceutical companies. He will be based in the United States.
    Bernhardt Zeiher, MD, the current CMO, will retire on September 30, 2022.
  • Change of name from CAO & CECO to CPO & CECO and appointment of CPO & CECO
    Effective October 1, 2022, the name of Chief Administrative Officer and Chief Ethics & Compliance Officer (CAO & CECO) will be renamed Chief People Officer and Chief Ethics & Compliance Officer (CPO & CECO). With the increasing emphasis on human capital in business management, change signifies the leadership role of this position in transforming human resources and the organization as a whole. Katsuyoshi Sugita will be appointed CPO & CECO from October 1, 2022. He has held human resources leadership positions in the pharmaceutical and technology industries and joined Astellas as a human resources manager in May 2021.
    Since joining Astellas, Mr. Sugita has leveraged his extensive HR experience and expertise to drive innovation and the active engagement of HR in achieving the organizational health goals set out in the “Corporate Strategic Plan 2021”.
    Fumiaki Sakuraithe current CAO & CECO, will retire on September 30, 2022.

“I would like to express my sincere gratitude to Mr. Sakurai and Dr. Zeiher for their tremendous contribution to Astellas,” said Kenji Yasukawa, President and CEO, Astellas. He added, “I expect Dr. Taniguchi to be focused on accelerating the clinical application of science, enriching our clinical portfolios, and delivering VALUE to patients. I am also confident that Mr. Sugita will further the achievement of organizational health goals by leveraging his long career. in the field of HR. United under this new leadership, Astellas aims to achieve the goals set out in the 2021 Corporate Strategic Plan.”

TOP Management (Workforce October 1, 2022)


Last name


Managing Director,

President and Chief Executive Officer (CEO)

Kenji Yasukawa

Managing Director,

Corporate Executive Vice President,

Director of Strategy (CStO)

Naoki Okamura

Commercial Director (CCO)

Yukio Matsui

Scientific Director (CScO)

Yoshitsugu Shitaka

Chief Financial Officer (CFO)

Minoru Kikuoka

General Counsel (GC)

Catherine Levitt

Director of Manufacturing (CMfgO)

Hideki Shima

Chief Medical Officer (CMO)

Tadaaki Taniguchi

Chief People Officer (CPO) and Chief Ethics & Compliance Officer (CECO)

Katsuyoshi Sugita

2Change of responsibility of the Corporate Officer (Entry into force October 1, 2022)

Tadaaki Taniguchi
New: Chief Medical Officer (CMO)
Current: Executive Advisor

Katsuyoshi Sugita
New: Chief People Officer (CPO) and Chief Ethics & Compliance Officer (CECO)
Current: Head of Human Resources Division

3. Resignation of the Corporate Officer (Workforce September 30, 2022)

Fumiaki Sakurai, Chief Administrative Officer (CAO) and Chief Ethics and Compliance Officer (CECO)

Bernhardt Zeiher, Chief Medical Officer (CMO)


Last name: Tadaaki Taniguchi
Professionnal career:

July 2022

Executive Advisor, Astellas Pharma Inc. (current position)

December 2021

SVP, Head of Asia Strategy, Oncology Business Unit, AstraZeneca PLC

November 2019

SVP, Head of Global Medical Affairs, Oncology Business Unit, AstraZeneca PLC

January 2019

SVP, Japan R&D Manager, AstraZeneca KK

April 2015

Vice President, Head of Japan Research and Development, Global Drug Development, AstraZeneca KK

December 2012

Vice President, Head of Research and Development Japan, Bristol-Myers Squibb KK

October 2011

Executive Director and Head of Strategy, China Development, MSD China

March 2006

Executive Director, Clinical Sciences, Deputy Director of Japan Development, MSD KK

January 2004

Senior Director, Clinical Research, Deputy Director of Clinical Development Institute, Banyu Pharmaceutical Co., Ltd.

March 2000

Research Manager, Clinical Development Institute, Banyu Pharmaceutical Co., Ltd.

November 1996

Clinical Researcher, Molecular Pathology Unit, Imperial Cancer Research Fund, Hammersmith Hospital, London

June 1991

Resident in Surgery, Tokyo Metropolitan Oncology and Infectious Disease Center Hospital

Last name: Katsuyoshi Sugita
Professionnal career:

May 2021

EVP, Human Resources Manager,

Astellas Pharma Inc. (current position)

July 2016

Human Resources Manager, Microsoft Japan Co., Ltd.

August 2012

Human Resources Manager, AstraZeneca KK

November 2008

Human Resources Manager, Hilti Japan Ltd.

September 2003

Johnson & Johnson K.K.

April 2002

ITOCHU Techno-Solutions Corp.

April 1991

Asahi Kasei Corp.

About Astellas
Astellas Pharma Inc. is a pharmaceutical company with operations in more than 70 countries around the world. We promote the focus area approach which is designed to identify opportunities for the continued creation of new medicines to treat diseases with high unmet medical need by focusing on biology and modality. Additionally, we are also looking beyond our core purpose of Rx to create Rx+® healthcare solutions that combine our expertise and knowledge with state-of-the-art technology in different areas from external partners. Through these efforts, Astellas is at the forefront of change in healthcare to turn innovative science into value for patients. For more information, please visit our website at

Cautionary Notes
In this press release, statements made regarding current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. These factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations relating to pharmaceutical markets, (ii) exchange rate fluctuations, (iii) delays in the launch of new products, (iv) Astellas’ inability to effectively market existing and new products, (v) Astellas’ inability to continue to effectively research and develop customer-accepted products in highly competitive markets, and (vi) violations of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products under development) that is included in this press release is not intended to constitute advertising or medical advice.

SOURCEAstellas Pharma Inc.